CD274 and neoplasm: Immune checkpoint inhibitors (ICIs) targeting programmed death-1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) have exhibited a durable response and currently dominate the method of treatment for various tumor types3-5.